Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients
with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver
transplant patients with chronic HBV infection. The aim of this prospective cohort study is
to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in
kidney or liver transplant patients with HBV infection.